

## GLP-1 Receptor Agonist Shortage

AHPPharmacist@urmc.rochester.edu

- **Pharmacies are reporting difficulty stocking higher doses of Trulicity® (dulaglutide 3 mg and 4 mg).** Highland Southwedge Pharmacy currently has the 3 mg dose in stock. Lower doses remain widely available.
- **Supplies of Ozempic® are improving but remain sporadic.** SMH Outpatient currently has the 1 mg dose and Highland Southwedge has a small number of the 0.25, 0.5 and 2 mg doses in stock.

As a reminder, UR pharmacies deliver and ship medications for no additional charge.

### Options for Managing GLP-1 Shortages

**Switch to an alternative agent in the class.** Victoza®, Rybelsus®, Bydureon®, and Byetta® remain available.

- Like Ozempic® and Trulicity®, there is an established CV benefit with Victoza®, though it is dosed once daily. To switch from a once weekly product, begin Victoza® on the day the next dose of Ozempic®/Trulicity® was due.
- Rybelsus® (oral semaglutide) has not demonstrated CV benefit and seems to have less benefit for weight loss.
- Bydureon® is once weekly but exenatide products have not demonstrated CV benefit.
- Byetta® is dosed twice daily but tends to be less tolerable than longer acting agents.

GLP-1	Frequency	Equivalent Dose					Savings Resources
Exenatide (Byetta®)	Twice daily	5 mcg	10 mcg				Coupon: NA <a href="#">Assistance application</a>
Exenatide (Bydureon®)	Once weekly			2 mg			<a href="#">Coupon</a> <a href="#">Assistance application</a>
Liraglutide (Victoza®)	Once daily	0.6 mg	1.2 mg	1.8 mg			Coupon: NA <a href="#">Assistance application</a>
Dulaglutide (Trulicity®)	Once weekly		0.75 mg	1.5 mg	3 mg	4.5 mg	<a href="#">Coupon</a> <a href="#">Assistance application</a>
Semaglutide (Ozempic®)	Once weekly		0.25 mg	0.5 mg	1 mg	2 mg	Availability of 1 mg and 2 mg strengths is sporadic
Semaglutide (Rybelsus®)	Once daily (oral)	3 mg	7 mg	14 mg			<a href="#">Coupon</a> <a href="#">Assistance application</a>

### Consider GLP-1/GIP receptor agonist Mounjaro® (tirzepatide).

- Tirzepatide is a new GLP-1/GIP receptor agonist which showed superior improvement in A1C and weight when compared to semaglutide 1 mg. CV studies are ongoing and benefits have not been established.
- The recommended starting dose is 2.5 mg weekly x 4 weeks. It is reasonable to attempt to convert patients on higher dose therapies (≥ Ozempic 1 mg or equivalent) to tirzepatide 5 mg with the understanding GI adverse effects may occur.

### Consider GLP-1 combination products for patients also on basal insulin.

GLP-1-Combination	Maximum Basal Insulin Dose	Savings Resources
insulin glargine-lixisenatide (Soliqua®)	60 units/day	<a href="#">Coupon</a> <a href="#">Assistance application</a>
insulin degludec-liraglutide (Xultophy®)	50 units/day	Coupon: NA <a href="#">Assistance application</a>